Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor
- PMID: 17441749
- DOI: 10.1021/pr070036r
Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor
Abstract
The virulence antigen (V-antigen, LcrV) of Yersinia pestis, the causative agent of bubonic plague, is an established protective antigen known to regulate, target, and mediate type III translocation of cytotoxic yersiniae outer proteins termed Yops; LcrV also prompts TLR2-dependent upregulation of anti-inflammatory IL-10. In this study, we determined the parameters of specific interaction of LcrV with TLR2 expressed on human transfected HEK293 cells (TLR2+/CD14-), VTEC2.HS cells (TLR2+/CD14-), primary monocytes (TLR2+/CD14+), and THP-1 cells (TLR2+/CD14+). The IRRL314-317 motif of the extracellular domain of human and mouse TLR2 accounted for high-affinity binding of LcrV. The CD14 co-receptor did not influence this interaction. LcrV did not bind to human U937 (TLR2-/CD14-) and alveolar macrophages (TLR2-/CD14+) in the absence of receptor-bound human IFN-gamma or a synthetic C-terminal fragment (hIFN-gamma132-143). The latter, but not mouse IFN-gamma (or synthetic control peptides), shared a GRRA138-141 site necessary for high-affinity specific binding. LcrV of Y. pestis shares the N-terminal LEEL32-35 binding site of Yersinia enterocolitica and also has an exposed internal DEEI203-206 binding site. Comparison of binding constants and consideration of steric restrictions indicate that binding is not cooperative and only the internal site binds LcrV to target cells. Both the LEEL32-35 and DEEI203-206 binding sites are removed by five amino acids from DKN residues associated with biological activity of bound LcrV. LcrV of Y. pestis promoted both TLR2/CD14-dependent and TLR2/CD14-independent amplification of IL-10 and concomitant downregulation of TNF-alpha in human target cells. The ability of LcrV to utilize human IFN-gamma (a major inflammatory effector of innate immunity) to minimize inflammation is insidious and may account in part for the severe symptoms of plague in man.
Similar articles
-
Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6. Vaccine. 2008. PMID: 18304706
-
Binding of LcrV protein from Yersinia pestis to human T-cells induces apoptosis, which is completely blocked by specific antibodies.Int J Biol Macromol. 2019 Feb 1;122:1062-1070. doi: 10.1016/j.ijbiomac.2018.09.054. Epub 2018 Sep 12. Int J Biol Macromol. 2019. PMID: 30218736
-
A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence.Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16049-54. doi: 10.1073/pnas.0504728102. Epub 2005 Oct 20. Proc Natl Acad Sci U S A. 2005. PMID: 16239347 Free PMC article.
-
Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae.Clin Immunol. 2005 Mar;114(3):216-26. doi: 10.1016/j.clim.2004.07.013. Clin Immunol. 2005. PMID: 15721832 Review.
-
The V antigen of yersiniae: an overview.Contrib Microbiol Immunol. 1991;12:127-33. Contrib Microbiol Immunol. 1991. PMID: 1935079 Review. No abstract available.
Cited by
-
Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice.Infect Immun. 2010 Jun;78(6):2529-43. doi: 10.1128/IAI.00005-10. Epub 2010 Mar 22. Infect Immun. 2010. PMID: 20308296 Free PMC article.
-
Outsmarting the host: bacteria modulating the immune response.Immunol Res. 2008;41(3):188-202. doi: 10.1007/s12026-008-8021-5. Immunol Res. 2008. PMID: 18592144
-
Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria.Front Microbiol. 2011 Jul 4;2:142. doi: 10.3389/fmicb.2011.00142. eCollection 2011. Front Microbiol. 2011. PMID: 21772833 Free PMC article.
-
Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.Vaccine. 2008 Oct 16;26(44):5554-61. doi: 10.1016/j.vaccine.2008.08.007. Epub 2008 Aug 21. Vaccine. 2008. PMID: 18722493 Free PMC article.
-
Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.Vaccine. 2009 Aug 27;27(39):5363-70. doi: 10.1016/j.vaccine.2009.06.078. Epub 2009 Jul 9. Vaccine. 2009. PMID: 19596407 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials